| Ch Specialty Services Nm Llc | |
|
206 S Coronado Ave Espanola NM 87532-2792 | |
| (337) 991-9276 | |
| Not Available |
| Full Name | Ch Specialty Services Nm Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 206 S Coronado Ave, Espanola, New Mexico |
| Authorized Official Name and Position | Nicole Howard (SR VP OF ADMINISTRATIVE SERVICES) |
| Authorized Official Contact | 3379919276 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Ch Specialty Services Nm Llc 1509 Dulles Dr Lafayette LA 70506-3718 Ph: (337) 991-9276 | Ch Specialty Services Nm Llc 206 S Coronado Ave Espanola NM 87532-2792 Ph: (337) 991-9276 |
| NPI Number | 1346943685 |
|---|---|
| Provider Enumeration Date | 03/24/2023 |
| Last Update Date | 03/24/2023 |
| Medicare PECOS PAC ID | 5496120883 |
|---|---|
| Medicare Enrollment ID | O20230418000479 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346943685 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Nancy M Greces |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558384644 PECOS PAC ID: 2567364169 Enrollment ID: I20040123000639 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Lisa S Noya |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1619938677 PECOS PAC ID: 9133172000 Enrollment ID: I20050401000966 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Diane H Cummings |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538149190 PECOS PAC ID: 6608875075 Enrollment ID: I20061212000536 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Stephanie D Flores |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1083852271 PECOS PAC ID: 8820142334 Enrollment ID: I20090818000828 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Tanya T Bryndzia |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720064835 PECOS PAC ID: 9537121603 Enrollment ID: I20120120000604 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Amy L Bubbico |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598927683 PECOS PAC ID: 4183869423 Enrollment ID: I20130314000396 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Lilia M Pedrego |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770895054 PECOS PAC ID: 9830412824 Enrollment ID: I20141223002189 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Amit Bhandari |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1598929176 PECOS PAC ID: 3971773383 Enrollment ID: I20180201002254 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Naveen Kumar Gummadi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558711606 PECOS PAC ID: 1355677386 Enrollment ID: I20190729000776 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | David Arturo Rodriguez |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1780038828 PECOS PAC ID: 3971897216 Enrollment ID: I20190910002490 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Carmen Marcolina |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730720632 PECOS PAC ID: 9739513417 Enrollment ID: I20200106002121 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Kaleigh Roberts |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962007385 PECOS PAC ID: 1557774650 Enrollment ID: I20210111000829 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Rozita Dayani |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932706223 PECOS PAC ID: 2567875339 Enrollment ID: I20210115001764 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Antonio Gamboa |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154356780 PECOS PAC ID: 2264468222 Enrollment ID: I20210208000617 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Katrina Singh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609467182 PECOS PAC ID: 7517373723 Enrollment ID: I20210315000649 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Shenif Ladak |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1376948604 PECOS PAC ID: 5890018501 Enrollment ID: I20210715002020 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Jacqueline Hill |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336629740 PECOS PAC ID: 8426392093 Enrollment ID: I20220331001974 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Ashley Lauren Zurcher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023573359 PECOS PAC ID: 4284968363 Enrollment ID: I20220516000097 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
| Provider Name | Brian Cooper |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1366678963 PECOS PAC ID: 0547426223 Enrollment ID: I20230724003638 |
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
News Archive
Potential outbreaks of diseases such as Ebola and Lassa fever may be more accurately predicted thanks to a new mathematical model developed by researchers at the University of Cambridge.
While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.
Scientists have developed a brain implant that essentially melts into place, snugly fitting to the brain's surface. The technology could pave the way for better devices to monitor and control seizures, and to transmit signals from the brain past damaged parts of the spinal cord.
Cell Therapeutics, Inc. announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for Pixuvri (pixantrone dimaleate) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.
Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.
› Verified 5 days ago
Whole Self Recovery Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 509 W Pueblo Dr, Espanola, NM 87532 Phone: 506-747-3368 Fax: 505-367-0077 | |
El Centro Family Health Rio Arriba Health Commons Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2010 Industrial Park Rd, Espanola, NM 87532 Phone: 505-753-7218 Fax: 505-753-5815 | |
Presbyterian Medical Services Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 835 Spruce St, C & D, Espanola, NM 87532 Phone: 505-747-7400 Fax: 505-747-7403 | |
Valley First Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 411 S Santa Clara Bridge Rd, Espanola, NM 87532 Phone: 505-747-6939 Fax: 505-747-6816 | |
Espanola Advanced Center For Healing Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 509 W Pueblo Dr, Espanola, NM 87532 Phone: 505-747-3368 Fax: 505-747-3368 | |
El Centro Family Health Evhs Sbhc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1111 El Llano Rd, Espanola, NM 87532 Phone: 505-753-7357 Fax: 905-747-8659 |